Key Players
Competitive Landscape
Four supplier types compete in the contact dermatitis market: disease-specific medical dermatology companies, diversified generic manufacturers, specialty topical formulation developers and regional prescription labelers.
Commercial investment has concentrated on disease-specific nonsteroidal creams and regulated high-potency corticosteroid supply since 2025. LEO Pharma expanded the Anzupgo launch to five markets in May 2025 to widen specialist access across regional dermatology channels. J. Molner launched clobetasol propionate cream in the United States during November 2025 as its fourth prescription product in that market. Price remains relevant across established generic channels serving recurring prescriptions through hospital and retail pharmacies. Competition now turns on labeled indication and dosage-form breadth plus supply reliability across recurring prescriptions.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| In May 2025, LEO Pharma expanded the Anzupgo launch to five markets across its medical dermatology network. | Dermatologists need a disease-specific topical option for adults whose chronic hand eczema does not respond to corticosteroids. | Branded competition is shifting from broad eczema portfolios toward indication-specific nonsteroidal creams supported by national approvals. | Additional country launches provide revenue through specialist prescribing and repeat pharmacy supply for chronic hand eczema treatment. |
| In October 2025, LEO Pharma reported Chinese NDA acceptance for Anzupgo in chronic hand eczema treatment. | Chinese dermatology centers require locally authorized therapies for persistent hand eczema that remains uncontrolled by topical corticosteroids. | Successful dermatology brands are entering new countries through sequential regulatory filings instead of simultaneous global commercialization. | Chinese hospital and retail channels provide revenue once regulatory approval supports specialist prescribing and dependable local distribution. |
| In November 2025, J. Molner launched clobetasol propionate cream as its fourth United States prescription product. | Hospital and retail pharmacies need additional regulated sources for high-potency topical corticosteroids used in corticosteroid-responsive dermatoses. | Specialist topical developers are entering mature generic dermatology channels through focused launches and regulated manufacturing partnerships. | Reliable clobetasol supply provides revenue across hospital and retail channels serving recurrent corticosteroid-responsive inflammatory skin conditions. |
Glenmark Pharmaceuticals Inc., USA, Oceanside Pharmaceuticals, Sun Pharmaceutical Industries, Inc., Alembic Pharmaceuticals Limited, Lupin Pharmaceuticals, Inc., E. Fougera & Co. and Encube Ethicals, Inc. compete on label breadth and dosage-form coverage, with no additional market-relevant launch or approval announced from January 2025 through July 2026.
Source: Future Market Insights, Contact Dermatitis Market and Hand Eczema Treatment Market Reports, 2026-2036.
LEO Pharma and J. Molner cover disease-specific nonsteroidal treatment and high-potency corticosteroids, while Glenmark adds current calcineurin inhibitor and corticosteroid labels across United States prescription channels.
Who leads the contact dermatitis market?
LEO Pharma leads the profiled field on disease-specific chronic hand eczema authorization following FDA approval of Anzupgo in July 2025. J. Molner competes through high-potency clobetasol cream launched in the United States during November 2025.
Which suppliers have documented regulatory approvals?
LEO Pharma holds FDA approval for Anzupgo in adults with moderate-to-severe chronic hand eczema following inadequate topical corticosteroid response. J. Molner’s clobetasol cream entered United States channels under ANDA 209411 through an FDA-listed labeler and manufacturing record.
Which companies provide topical corticosteroid and calcineurin inhibitor products?
Glenmark supplies pimecrolimus cream and tacrolimus ointment alongside clobetasol cream in regulated United States channels. Fougera combines tacrolimus ointment with clobetasol solution, while Encube supplies clobetasol solution and ointment through current prescription labels.
Which suppliers serve North America and Europe?
LEO Pharma markets Anzupgo across North America and several European countries through its medical dermatology network. J. Molner AS develops the clobetasol cream supplied by its United States labeler from a Canadian manufacturing site.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| LEO Pharma A/S | Global | Anzupgo cream for moderate-to-severe chronic hand eczema (five-market expansion in May 2025). |
| J. Molner AS | Europe and United States | Clobetasol propionate 0.05% emollient cream (United States launch in November 2025). |
| Oceanside Pharmaceuticals | United States | Pimecrolimus cream and hydrocortisone butyrate cream through current prescription labels. |
| Glenmark Pharmaceuticals Inc., USA | United States | Pimecrolimus cream, tacrolimus ointment and clobetasol cream through current prescription labels. |
| Sun Pharmaceutical Industries, Inc. | United States | Clobetasol propionate topical solution through a current prescription label. |
| Alembic Pharmaceuticals Limited | United States | Clobetasol propionate cream and ointment through current prescription labels. |
| Lupin Pharmaceuticals, Inc. | United States | Clobetasol propionate cream and lotion through current prescription labels. |
| E. Fougera & Co. | United States | Tacrolimus ointment and clobetasol topical solution through current prescription labels. |
| Encube Ethicals, Inc. | United States | Clobetasol propionate solution and ointment through current prescription labels. |
Research Methodology
The companies here show how contact dermatitis treatment competition is structured and do not form a ranking. Inclusion requires current evidence confirming prescription topical products for eczema or corticosteroid-responsive dermatoses through regulator labels, company announcements, filings or approval records. Registrations belong to the named labeler or legal entity, and the 39.0% topical corticosteroid share remains an FMI estimate for 2026.
